Adma Biologics earnings were $146.9M for the trailing 12 months ending Dec 31, 2025, with -27.1% growth year over year. The latest ADMA earnings report on Dec 31, 2025 announced Q4 2025 earnings of $49.4M, up 35.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ADMA reported annual earnings of $146.9M, with -25.7% growth.
ADMA past earnings growth
How has ADMA's earnings growth performed historically?
On ADMA's earnings call on Invalid Date, Adma Biologics (NASDAQ: ADMA) reported Q4 2025 earnings per share (EPS) of $0.21, up 56.25% year over year. Total ADMA earnings for the quarter were $49.38 million. In the same quarter last year, Adma Biologics's earnings per share (EPS) was $0.48.
As of the last Adma Biologics earnings report, Adma Biologics is currently profitable. Adma Biologics's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $146.93 million, a 25.67% decrease year over year.
What was ADMA's earnings growth in the past year?
As of Adma Biologics's earnings date in Invalid Date, Adma Biologics's earnings has grown -27.06% year over year. This is 109.57 percentage points lower than the US Biotechnology industry earnings growth rate of 82.51%. ADMA earnings in the past year totalled $146.93 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.